Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.

ABSTRACT:

Importance

With few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatric-onset multiple sclerosis (POMS).

Objective

To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon β-1a (IFNβ-1a) in POMS.

Design, setting, and participants

The CONNECT study was an active-controlled, open-label, rater-blinded 96-week randomized clinical trial in patients with POMS aged 10 to less than 18 years treated between August 2014 and November 2020. Data were analyzed from January through October 2021.

Interventions

Patients were randomized to DMF or IFNβ-1a.

Main outcomes and measures

The primary end point w

SUBMITTER: Vermersch P 

PROVIDER: S-EPMC9520348 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature